Oric Pharmaceuticals, Inc. (ORIC) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$9.97

From 52W high−37.97%

Volume1.74M

Market cap$941.96M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$9.97

From 52W high

−37.97%

Volume

1.74M

Market cap

$941.96M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.8x

P/E (TTM)

—

RSI (14)

34.6

MomentumView details →

1D Return

−5.24%

YTD Return

+11.37%

SummaryUpdated Jun 1, 2026

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in South San Francisco, California. The company went public in April 2020 and focuses on discovering and developing precision cancer therapies that target specific resistance mechanisms in oncology. ORIC operates as a research-driven organization that aims to overcome the challenges patients face when their cancers become resistant to existing treatments, including both chemotherapy and newer immunotherapy approaches.

Ask drillr about Oric Pharmaceuticals, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−4.8x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

2.5x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−36.81%

ROA (TTM)

−34.68%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+28.57%

FCF YoY

+7.52%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+19.67%

EBITDA YoY

−2.29%

MomentumView details →

1D Return

−5.24%

YTD Return

+11.37%

1Y Return

−26.41%

RSI (14)

34.6

vs 50D SMA

−25.25%

vs 200D SMA

−17.94%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

13.19x

Quick Ratio

13.19x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.38

EPS Surprise

−5.75%

Beats (12Q)

7/12

Next Q EPS Est

−$0.40

Avg Surprise (4Q)

1.50%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−140.35M

Op. CF (TTM)

−111.64M

Next earningsNov 12, 2026 →

Latest newsMore news →

Oric Pharmaceuticals, Inc. presented enozertinib data for first-line NSCLC patients with EGFR atypical mutations at the ESMO Congress 2026.12d ago

Oric Pharmaceuticals, Inc. announced that it will host a conference call and webcast on October 23, 2026, to review enozertinib data presented at the Oric Pharmaceuticals, Inc..16d ago

Similar companies

Inventiva S.A.IVA MoonLake ImmunotherapeuticsMLTX Savara Inc.SVRA Jade Biosciences, Inc.JBIO Pharming Group N.V.PHAR Syndax Pharmaceuticals, Inc.SNDX Find similar companies →

Latest newsMore news →

Oric Pharmaceuticals, Inc. presented enozertinib data for first-line NSCLC patients with EGFR atypical mutations at the ESMO Congress 2026.12d ago Oric Pharmaceuticals, Inc. announced that it will host a conference call and webcast on October 23, 2026, to review enozertinib data presented at the Oric Pharmaceuticals, Inc..16d ago ORIC Pharmaceuticals announced an agreement with Cancer Research UK under which Cancer Research UK will fund, sponsor, design, and execute CTA-enabling studies and Phase 1/2 clinical development of ORIC-259, a CIP2A-targeted therapy, while ORIC retains an exclusive option to reacquire rights after Phase 1/2 data.30d ago